A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CKD-508 in Healthy Participants.

This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.

Study Overview

• Status: Completed
• Conditions: Healthy Subjects
• Intervention / Treatment: Drug: CKD-508 Tablet; Drug: Placebo Tablet

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Glendale, California, United States, 91206
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• The participant is capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.
• Male and female adults aged 18 to 55 years at screening.
• Healthy participants were determined by pre-study medical evaluation and judged by the Investigator.
• Female participants of non-childbearing potential (surgically sterile [hysterectomy or oophorectomy]) or postmenopausal (amenorrhea for more than 12 months with follicle-stimulating hormone [FSH] in the postmenopausal range as confirmed by an FSH test).
• Female participants of childbearing potential who agree to use highly effective method of contraception in the protocol consistently and correctly from screening until the last dose administration of the study intervention.
• Male participants must be unable to procreate (defined as surgically sterile [had a vasectomy] ≥6 months prior screening) or must agree to use a highly effective contraception as detailed in the protocol during the intervention period and for at least 90 days after the study completion and refrain from donating sperm during this period.
• Non-smoker (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (<200 ng/mL) at screening and admission.

Exclusion Criteria:

• History or evidence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder as determined by the Investigator.
• Presence of any disorder that would interfere with the absorption, distribution, metabolism, or excretion of study intervention as judged by the Investigator.
• Serum alkaline phosphatase (ALP) or total bilirubin ≥upper limit of normal (ULN), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >ULN at either screening or admission.
• Abnormal renal function with estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2 at screening.
• History or presence of clinically significant abnormal cardiac automaticity, heart rhythm, ECG findings, or other relevant conditions that may pose a risk to the participants as judged by the Investigator.
• History of alcohol and/or illicit drug abuse within 2 years before screening or positive urine test for alcohol or positive urine drug test at screening or admission.
• Positive test for HBsAg, HCV RNA, or HIV antibody at screening.
• Currently taking a lipid-modifying medication.
• History of hypersensitivity to CKD-508 or medicinal products with similar chemical structures.
• Individual unlikely to comply with the protocol requirements, instructions, and study-related restrictions.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CKD-508 dose level 1; Multiple dose of CKD-508 tablets	Drug: CKD-508 Tablet; Investigational drug
Experimental: CKD-508 dose level 2; Multiple dose of CKD-508 tablets	Drug: CKD-508 Tablet; Investigational drug
Experimental: CKD-508 dose level 3; Multiple dose of CKD-508 tablets	Drug: CKD-508 Tablet; Investigational drug
Experimental: CKD-508 dose level 4; Multiple dose of CKD-508 tablets	Drug: CKD-508 Tablet; Investigational drug
Placebo Comparator: Placebo; Multiple dose of placebo tablets	Drug: Placebo Tablet; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)	An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE will be defined as any AE that emerges during treatment (i.e., AE which starts during or after study drug administration or pre-existed and worsened in severity after study drug administration), and those will be analyzed for the purpose of safety analysis. The number of participants who experience a TEAE will be reported.	up to Day 56
Maximum Plasma Concentrations of CKD-508 after single and multiple doses	Peak plasma concentration (Cmax)	up to Day 56
Time to Maximum Plasma Concentrations of CKD-508 after single and multiple doses	Time of peak plasma concentration (Tmax)	up to Day 56
Area Under the Concentration-Time Curve of CKD-508 after single dose	Area under the concentration-time curve from pre-dose (time 0) to post-dose 24 h (AUC0-24h) after a single dose	up to 24 hours post-dose
Area Under the Concentration-Time Curve of CKD-508 after multiple doses	Area under the concentration-time curve from pre-dose (time 0) to post-dose 24 h (AUCtau.ss) after multiple doses	up to Day 56
Change from baseline in CETP activity after multiple doses of CKD-508 or placebo	The absolute values and percentages of change from baseline in CETP activity measured in blood after multiple doses of CKD-508 or placebo	up to Day 56

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) after multiple doses of CKD-508 or placebo	The absolute values and percentages of change from baseline in LDL-C measured in blood after multiple doses of CKD-508 or placebo	up to Day 40
Change from Baseline in High-density Lipoprotein Cholesterol (HDL-C) after multiple doses of CKD-508 or placebo	The absolute values and percentages of change from baseline in HDL-C measured in blood after multiple doses of CKD-508 or placebo	up to Day 40
Change from Baseline in CETP mass after multiple doses of CKD-508 or placebo	The absolute values and percentages of change from baseline in CETP protein concentration measured in blood after multiple doses of CKD-508 or placebo	up to Day 56
The effects on the cardiac repolarization by assessing the QTc interval after single and multiple doses of CKD-508 or placebo		up to Day 56

Collaborators and Investigators

• Sponsor: Chong Kun Dang Pharmaceutical

Study record dates

Study Major Dates

• Study Start (Actual): November 14, 2024
• Primary Completion (Actual): June 5, 2025
• Study Completion (Actual): June 5, 2025

Study Registration Dates

• First Submitted: December 2, 2024
• First Submitted That Met QC Criteria: December 6, 2024
• First Posted (Actual): December 10, 2024

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 25, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: A104_02PK2405

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No